Answers are grounded in this paper and cite their sources.
Our results suggest that overexpression of Integrin-αV and -α5 are likely contributing to secondary pathologies in MDC1A. We also believe that downregulation of Integrin-αV could be partially responsible for Losartan's antifibrotic effect and therefore could serve as a novel therapeutic target in MDC1A and other degenerative fibrotic diseases.
No takes yet. Share an insight, caveat, or question.
Accorsi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: